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Abstract
Background: Febrile seizures are associated with the first dose of measles-containing vaccines 
and the risk increases with chronologic age during the second year of life. We used the Vaccine 
Safety Datalink (VSD) to determine if the relative increase in risk of seizures following receipt of 
measles-containing vaccine differs by gestational age at birth.
Methods: Children were eligible if they received their first dose of measles-containing vaccine at 
age 12 through 23 months from January 2003 through September 2015. Children were excluded if 
they had a history of seizure or conditions strongly related to seizure prior to 12 months of age. 
Seizures were identified by diagnostic codes in the inpatient or emergency department settings. 
Using risk-interval analysis, we estimated the incidence rate ratio (IRR) for seizures in the 7 
through 10 days (risk period) vs 15 through 42 days (control period) following receipt of measles-
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containing vaccines in children born preterm (<37 weeks gestation age) and those born full-term 
(≤37 weeks).
Results: There were 532,375 children (45,343 preterm and 487,032 full-term) who received their 
first dose of measles-containing vaccine at age 12 through 23 months. The IRRs of febrile seizures 
7 through 10 days compared with 15 through 42 days after receipt of measles-containing vaccine 
were 3.9 (95% CI: 2.5–6.0) in preterm children and 3.2 (2.7–3.7) in full-term children; the ratio of 
IRRs: was 1.2 (0.76–1.9), p = 0.41. IRRs were also similar across gestational age groups, by 
vaccine type received (measles-mumps-rubella [MMR] or measles-mumps-rubella-varicella 
[MMRV]) and age at vaccination (12–15 or 16–23 months).
Conclusion: Vaccination with a measles-containing vaccine in the second year of life is 
associated with a similar relative risk of a first seizure in children born preterm as in those who 
were born full-term.
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1. Background
Combination measles-mumps-rubella (MMR) and measles-mumps-rubella-varicella 
(MMRV) vaccines are two measles-containing vaccines currently available in the United 
States [1]. Measles-containing vaccines are associated with an increased risk of febrile 
seizures in the second week after vaccination [2–8]. Among children aged 12 through 23 
months, the risk of febrile seizures is approximately 2 times higher in those who received the 
first dose as MMRV vaccine compared to those who received separate MMR and varicella 
vaccines at the same visit [5,9]. Age at vaccination has also been associated with risk of 
seizures. Children who received their first dose of measles-containing vaccine at age 16–23 
months had a higher risk of seizures than those vaccinated at age 12–15 months, the age 
recommended by the U.S. Advisory Committee on Immunization Practices (ACIP) [1,6,10]. 
Although the biological mechanism for febrile seizures is unclear, the age associated risk is 
likely due to multiple factors, including peak incidence of febrile seizures occurring at age 
15–18 months [11] and maturation of the brain’s sensitivity to fever [12]. Additionally, 
differences in the underlying medical conditions or health-seeking behaviors may exist 
between those who are vaccinated at the recommended age versus those who receive it later 
[6]. Parents of preterm infants may delay MMR vaccination for their child [13,14], as the 
incidence of febrile seizures is higher in children who are born preterm than those born full-
term [15–17]. However, data concerning the safety of vaccination in children born preterm 
compared to children born full-term is limited particularly for vaccinations received during 
the second year of life [18,19].
We aimed to examine if the risk of febrile seizures during the 7 through 10 days versus 15 
through 42 days following receipt of measles-containing vaccine is increased in children 
born preterm compared to children born full-term. We also assessed whether the difference 
in risk of febrile seizures following receipt of measles-containing vaccine (if any) might vary 
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by vaccine type received (MMR or MMRV) or age at vaccination (12 through 15 or 16 
through 23 months).
2. Methods
2.1. Study population
The study population consisted of children who received their first dose of measles-
containing vaccine at age 12 through 23 months from January 1, 2003 through September 
30, 2015. These children were members at seven integrated health care organizations (sites) 
located throughout the United States that participate in the Centers for Disease Control and 
Prevention (CDC) sponsored Vaccine Safety Datalink (VSD) [20,21]. Institutional Review 
Boards at each VSD site approved this study with a waiver of informed consent.
Children were included if they were born at a study site facility, were continuously enrolled 
as members of the study site to age 24 months, and had gestational age data. Estimated 
gestational age at birth was determined from the VSD pregnancy algorithm [22]. In brief, the 
algorithm captures gestational age from each site’s electronic medical record databases (e.g., 
procedure dates, ultrasound reports, laboratory tests and dates) and supplemented with birth 
certificate data from the corresponding state vital records office. When gestational age was 
not available, it was imputed using published outcome specific averages or definitions. [22]. 
We classified children born before 37 weeks gestational age as preterm and children born 37 
weeks gestational age as full term [23]. We also further classified preterm into those born 
<35 weeks (early preterm) and 35 through 36 weeks (late preterm) gestational age. Children 
with epilepsy, cerebral palsy, severe head trauma, intraventricular hemorrhage, intracranial 
tumor, meningitis, or encephalitis based on documented International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnostic codes in the electronic 
medical record were excluded (Supplemental Table). Children with an ICD-9-CM coded 
diagnosis of seizure prior to 12 months of age were also excluded. The exclusion criteria 
were determined by consensus of coauthors and were conditions known to be associated 
with increased risk of seizures or recurrence of seizures.
Supplementary data associated with this article can be found, in the online version, at https://
doi.org/10.1016/j.vaccine.2018.11.038.
2.2. Outcome
A seizure was defined as the first emergency department or inpatient hospital encounter with 
ICD-9-CM diagnostic code of 780.3 (convulsions) during the 42-days following vaccination; 
we did not distinguish between febrile and afebrile seizures. However, previous VSD studies 
have found a high confirmation rate (94% for acute seizures, 87% for acute febrile seizures) 
for this diagnostic code when assigned from emergency department or inpatient hospital 
encounters [5,6,16,24].
2.3. Analytic approach
We conducted a risk-interval analysis among vaccinated children [25] with each child having 
42 days of follow-up following receipt of a measles-containing vaccine. Days 7 through 10 
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following vaccination were defined as the risk interval and days 15 through 42 following 
vaccination were defined as the control interval. Days 0 through 6 and 11 through 14 
following vaccination were excluded. The first exclusion reduced possible short-term effects 
with concomitant vaccines [3,26–28] and the latter exclusion was to avoid residual exposure 
effects in the control interval. Children with seizures occurring in these excluded intervals 
were excluded in the analysis.
Seizure incidence rates and 95% confidence intervals per 1000 person-years were calculated 
for the risk and control intervals. To examine the possible effect of gestational age 
differences, we compared the incidence rate ratios (IRRs) of seizures between children born 
preterm and those born full-term using a Poisson regression model with an effect-
modification term for gestational age category by exposure status (risk or control interval). 
The effect modification estimate was expressed as the ratio of IRRs with its 95% confidence 
interval and p-value [29]. Separate models were generated by vaccine received (MMR and 
MMRV) and by child’s age at vaccination (12 through 15 and 16 through 23 months) since 
seizure risk following vaccination differ by vaccine type and age at vaccination, respectively 
[5–7].
We also performed a temporal scan of all cases within 1 through 42 days post vaccination 
interval [30] to determine if the 7 through 10 day risk interval was appropriate for the 
gestational age categories, vaccine received, and child’s age at vaccination. Periods in the 1 
through 42 days post vaccination among the largest log-likelihood were considered clusters 
for further analysis.
All analyses were performed in SAS 9.4 (SAS Institute, Cary, NC).
3. Results
There were 556,864 children who received their first dose of measles-containing vaccine at 
age 12 through 23 months. Of these, 24,489 children were excluded because of documented 
history of seizure before age 12 months (<1%) or other exclusionary diagnoses (4%). The 
remaining 532,375 children were included in the analysis; 45,343 were born preterm (8.5%) 
and 487,032 born full-term (91.5%). There were no meaningful differences between those 
born preterm and full-term by sex, age at vaccination, or maternal age (Table 1). As 
expected, children born preterm had lower mean birth weights (30% less) than those born 
full-term.
Of the 996 children with a seizure episode during the 42 days following vaccination, 167 
seizures occurred 0 through 6 or 11 through 14 days after vaccination and were excluded. 
The remaining 829 children with seizures were included in the analysis; 87 in children born 
preterm (32 in children born <35 weeks gestational age and 55 in children born 35 through 
36 weeks) and 742 in those born full-term. Seizures occurred in the 7 through 10 days post-
vaccination risk period in 263 children and in the 15 through 42 days post-vaccination 
control period in 566 children. The mean age at seizure events were similar for both children 
born preterm (13.5 months) and children born full-term (13.3 months).
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In the overall primary analysis, the IRR point estimate of children born preterm was 20% 
larger than children born full-term, although the precision was low [ratio of IRRs: 1.2 (0.76–
1.9), p = 0.41], (Table 2). From the secondary analyses, similar IRR results were observed 
for children born <35 weeks or 35 through 36 weeks gestational age, among those receiving 
MMR or MMRV, and children vaccinated at age 12 through 15 months. For children 
vaccinated at age 16 through 23 months, the point estimate IRR was 20% lower for children 
born preterm vs full-term; precision was also low [ratio of IRRs: 0.82 (0.20–3.4), p = 0.79]. 
Overall, and for all vaccine and age strata, the risk-interval (exposed) incidence rates were 
20–40% larger for children born preterm vs. full-term. The largest incidence rate point 
estimate was for children born preterm who received MMRV (100 seizures per 1000 person-
years). The lowest point estimate (10 seizures per 1000 person-years) was observed for full-
term children vaccinated at age 16 through 23 months during the unexposed control interval.
Temporal scans showed that the 7 through 10 day post-vaccination period was identified as a 
high-risk cluster overall and in the gestational age and vaccine type subgroups 
(Supplemental Figures).
4. Discussion
We examined the incidence rates and incidence rate ratios of seizures following receipt of 
measles-containing vaccine in the second year of life by gestational age for children without 
previous seizures or seizure-related disorders. Generally, the exposed incidence rate and IRR 
point estimates were similar among children born pre-term compared to full-term. The ratio 
of IRRs in the two groups were near 1, with 95% confidence intervals that ranged from <1 to 
substantially >1. Infants born preterm are recommended to receive vaccinations at the same 
chronological age recommended for infants born full-term [31]. Existing data for 
vaccination of preterm infants are reassuring with no apparent safety concerns, and although 
immune response to vaccines in the first year of life may be lower for infants born preterm 
than full-term, the differences are likely to be not clinically relevant [32]. For vaccinations 
received during the second year of life, differences in immune response between preterm 
and full-term are less significant [33]. In our study, the overall incidence rate of seizures 
following vaccination was low and the incidence rate ratios essentially did not differ 
between children born preterm and those born full-term. The increased risk with delayed 
receipt of measles-containing vaccine or with receipt of MMRV is consistent with previous 
VSD studies [5–7], and is unrelated to gestational age.
This was a large population based study with highly accurate vaccination dates [34] and use 
of previously validated diagnostic codes for the seizure outcome [5,6,16,24]. However, our 
study had several potential limitations. First, we did not include children who may have 
delayed receipt of measles-containing vaccine past age 23 months. Second, there were 
relatively few seizure cases among children born preterm, particularly among those who 
were vaccinated after age 15 months and those who received MMRV vaccine. Third, most of 
the preterm children were born at 35 through 36 weeks gestational age (late preterm) while 
few children were born at <35 weeks gestational age. Finally, we excluded children with a 
previous history of seizure or risk factors related to seizure so our results may not apply to 
this population. Notably, “personal or family history of seizures” is a precaution (but not a 
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contraindication) of measles-containing vaccines [1]. We excluded children with a personal 
history of seizures before 12 months of age, based on electronic diagnostic codes, in our 
attempt to independently assess the risk of seizures due to measles-containing vaccines 
among children born preterm. We were not able to assess family history, as data were not 
readily available in the electronic health record.
In conclusion, our results support the current ACIP recommendations to administer the first 
dose of measles-containing vaccine at age 12 through 15 months for all children, including 
those born preterm [1,13,31]. Delaying vaccination of measles-containing vaccines may 
increase the risk of seizures following vaccination.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Characteristics of children aged 12–23 months at the time of receipt of first dose of measles-containing 
vaccine by gestational age.
Gestational age category (weeks)
Preterm (<37) Full-term (≤37)
Number of children 45,343 487,032
Vaccine received, n (%)
MMR 37,262 (82.2) 403,238 (82.8)
MMRV 8081 (17.8) 83,794 (17.2)
Sex, n (%)
Female 20,779 (45.8) 239,775 (49.2)
Male 24,564 (54.2) 247,257 (50.8)
Age at vaccination in months, mean (SD) 13.30 (1.98) 13.33 (2.01)
Calendar month of vaccination, n (%)
November through April 22,197 (49.0) 234,430 (48.1)
May through October 23,146 (51.0) 252,602 (51.9)
Birth weight in grams, mean (SD) 2417 (6 4 9) 3449 (4 7 4)
Maternal age in years, mean (SD) 31.9 (5.7) 31.1 (5.3)
Abbreviations: MMR, measles-mumps-rubella; MMRV, measles-mumps-rubella-varicella; SD, standard deviation.
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